{"id":"9d397fba-9069-5446-9f13-1f301699925a","stable_key":"10aa417f-4b03-599f-a453-4aa09edeb27c:alanine-liver-diabetes-context","predicate":"reduces","statement":"Hepatic Gpt2 suppression improved hyperglycemia in db/db mice, whereas liver-specific loss in lean mice did not similarly alter ordinary blood glucose.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"b3b9e25b-573b-5b05-932b-bf48e8fa4ac5","mechanism_event_label":"The consequence of blocking one pathway depended on metabolic state.","subject":{"id":"a51781f8-0e1f-5e46-8252-c450a16bffbc","slug":"mouse-liver-gpt2-suppression","display_name":"Hepatic Gpt2 suppression in mice","entity_type_key":"cellular_process"},"object":{"id":"0f8ddf35-9f56-5fc5-af86-fc5767addb8c","slug":"dbdb-mouse-hyperglycemia","display_name":"Hyperglycemia in db/db mice","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b3b9e25b-573b-5b05-932b-bf48e8fa4ac5","stable_key":"10aa417f-4b03-599f-a453-4aa09edeb27c:alanine-liver-diabetes-context-event","event_type":"observed_relationship","label":"The consequence of blocking one pathway depended on metabolic state.","description":"Hepatic Gpt2 suppression improved hyperglycemia in db/db mice, whereas liver-specific loss in lean mice did not similarly alter ordinary blood glucose.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a51781f8-0e1f-5e46-8252-c450a16bffbc","slug":"mouse-liver-gpt2-suppression","display_name":"Hepatic Gpt2 suppression in mice","entity_type_key":"cellular_process"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"0f8ddf35-9f56-5fc5-af86-fc5767addb8c","slug":"dbdb-mouse-hyperglycemia","display_name":"Hyperglycemia in db/db mice","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ebdc4461-c059-563e-88b0-422c21fdaa25","slug":"alanine","display_name":"L-Alanine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f78af6f3-4504-551f-b48b-dd25fcf5a629","slug":"mouse-gpt2","display_name":"Mouse mitochondrial alanine aminotransferase / Gpt2","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"8ae7848b-f172-5e09-8acf-5ca914907b0b","slug":"glucose","display_name":"D-glucose","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Diabetic and lean mouse genetic experiments.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not a demonstrated human diabetes treatment; compensatory pathways remain. Correction record: Published correction adds the originally omitted disclosure that B.N.F. was a scientific advisory board member and stockholder of Cirius Therapeutics, which develops MPC inhibitors. Disclosure correction, not a data retraction. https://pmc.ncbi.nlm.nih.gov/articles/PMC9713851/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Alanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"alanine","display_name":"L-Alanine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The consequence of blocking one pathway depended on metabolic state.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids. · 2022 · https://pubmed.ncbi.nlm.nih.gov/35476997/ · DOI 10.1016/j.celrep.2022.110733","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"ca71205f-6d52-5cbb-847f-ba1a1795103c","evidence_kind":"source_excerpt","locator":"Lines 232-238","start_line":232,"end_line":238,"excerpt":"## alanine-liver-diabetes-context\nThe consequence of blocking one pathway depended on metabolic state.\nHepatic Gpt2 suppression improved hyperglycemia in db/db mice, whereas liver-specific loss in lean mice did not similarly alter ordinary blood glucose.\nModel: Diabetic and lean mouse genetic experiments.\nLimitations: Not a demonstrated human diabetes treatment; compensatory pathways remain. Correction record: Published correction adds the originally omitted disclosure that B.N.F. was a scientific advisory board member and stockholder of Cirius Therapeutics, which develops MPC inhibitors. Disclosure correction, not a data retraction. https://pmc.ncbi.nlm.nih.gov/articles/PMC9713851/\nEvidence access: Primary full text\nSilencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids. · 2022 · https://pubmed.ncbi.nlm.nih.gov/35476997/ · DOI 10.1016/j.celrep.2022.110733","model_system":"Diabetic and lean mouse genetic experiments.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"01c5554c-a8ba-5c86-9b01-a0fa1a886cdb","stable_key":"import-10aa417f-4b03-599f-a453-4aa09edeb27c","title":"L-Alanine: carbon, nitrogen, protein synthesis and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"8ce7dd76c88b2e25fa23d93f9655a244aadb9d90f55ec8b18ecf0fd4625a61d2","revision_id":"4ed32258-0213-599a-a272-6f8f62280773","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}